Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Abby Rogers, DMSc, PA-C, MPAS
Advertisement
Articles by Abby Rogers, DMSc, PA-C, MPAS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
2
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
3
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
4
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
5
